Business Wire

TTNE: World Sauna Award "SAUNA37” 2025 Launched on March 7th

7.3.2025 14:00:00 EET | Business Wire | Press release

Share

TTNE Inc. (Headquarters: Tokyo, JAPAN) is proud to announce the release of SAUNA37 2025, a world sauna award dedicated to recognizing 37 destination saunas around the globe, on March 7th 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305835332/en/

SAUNA37 (Graphic: Business Wire)

Through this initiative, we aim to contribute to the global growth of sauna culture and create a future where people around the world can lead happier and healthier lives through saunas.

TTNE was founded by Totonoe Oyakata (Dai Matsuo) and Sauna Master (Daisuke Akiyama), who have personally experienced some of the world's finest saunas. Their desire to establish a similar deep-rooted sauna culture in Japan led to the creation of TTNE.

As people once again have the opportunity to explore sauna experiences around the world, SAUNA37 aims to introduce the diverse and unique sauna facilities and cultures across the globe. Through this initiative, we seek to further evolve Japan’s sauna culture while also sharing it with the world.

TTNE remains committed to the global evolution of sauna culture, continuously working to inspire and promote its growth worldwide.

SAUNA37
https://www.sauna37.com/
- Nominated 37 sauna facilities - *alphabetical order

  1. 7132 Thermel (Switzerland)
  2. AIRE Ancient Baths Barcelona (Spain)
  3. Amangalla (Sri Lanka )
  4. Banya Forrest (UAE)
  5. Banya No.1 Hoxton (UK)
  6. Bathhouse Flatiron (USA)
  7. BEAR AND BIRCH (USA)
  8. Claudius Therme (Germany)
  9. Hotel & Wellness Zuiver (Netherlands)
  10. Hotel Klosterbräu (Austria)
  11. Kilic Ali Pasa Hamami (Turkey)
  12. Kitakobushi Shiretoko Hotel & Resort (Japan)
  13. Kulttuuri Sauna (Finland)
  14. Neptunbad Sports & Spa (Germany)
  15. Nordik Spa-Nature Chelsea (Canada)
  16. Ohya Genki-ro No.06 (Japan)
  17. Othership Flatiron (USA)
  18. QC Terme San Pellegrino (Italy)
  19. Rauhaniemi Folk Spa (Finland)
  20. RING SPA & SAUNAS (Estonia)
  21. Rukan Salonki Chalets (Finland)
  22. Sataman Viilu (Finland)
  23. Sauna Hermanni (Finland)
  24. Saunaravintola Kuuma (Finland)
  25. Sheraton Addis (Ethiopia)
  26. Skywheel Helsinki (Finland)
  27. Tallinn Viimsi SPA (Estonia)
  28. TEPLO CONCEPT (Indonesia)
  29. Termy Rzymskie (Poland)
  30. The BANYA (Australia)
  31. The Well Spa & Hotel (Norway)
  32. Tsukahara Karafuro (Japan)
  33. Uusi Sauna (Finland)
  34. Vabali Spa Düsseldorf (Germany)
  35. Voda Spa (USA)
  36. Yasuragi (Sweden)
  37. Yunomori Onsen & Spa Pattaya (Thailand)

TTNE

Official site & Instagram
TTNE: https://ttne.jp @ttne_official
SHOP TTNE: https://www.ttne.shop
SAUNA SELECT: https://sauna-select.com @saunaselect
SAUNACHELIN: https://www.saunachelin.com@saunachelin_official
SAUNA37: http://sauna37.com @sauna37_official
HARVIA: https://www.harvia.com, https://harvia.jp, @harviaglobal, @harvia.jp

View source version on businesswire.com: https://www.businesswire.com/news/home/20250305835332/en/

Contacts

TTNE Inc.
contact@ttne.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye